799-P: Predictors of Glycemic Control by Derived Time in Range for People with Type 2 Diabetes Advancing with iGlarLixi—A Pooled Analysis
Authors: HRAMIAK IRENE , FRIAS JUAN P. , AYDIN HASAN , LAUAND FELIPE , MELAS-MELT LYDIE , SOUHAMI ELISABETH , HALUZIK MARTIN , ROSENSTOCK JULIO 
Published: June 2023

This post-hoc, pooled analysis of 3 randomized controlled trials aimed to identify factors associated with achieving a derived Time in Range (dTIR) ≥70% at the end of treatment (EOT) with iGlarLixi in people with type 2 diabetes (T2D).

dTIR was calculated from 7-point self-monitored plasma glucose (SMPG) profiles and assessed at baseline (BL) and EOT for people with T2D advancing from oral (LixiLan-O), insulin (LixiLan-L), or GLP-1 RA (LixiLan-G) therapy to once-daily iGlarLixi. Participants at EOT were classified as either achieving or not achieving dTIR ≥70%, and corresponding predictive BL characteristics were analyzed with univariable and multivariable stepwise logistic regression.

Analyses (N=880) showed that 86% of participants achieved dTIR ≥70% with iGlarLixi; T2D duration and HbA1c at BL were greater in those with dTIR &lt;70% (mean [SD] 11.35 [7.31] years and 8.26 [0.68] %) than those with dTIR ≥70% (10.40 [6.51] years and 7.96 [0.68] %), respectively. Post-meal SMPG at BL was higher in those not achieving dTIR ≥70%. Lower BL HbA1c (p=0.0205), BL insulin dose (p&lt;0.0001), and hypoglycemia level 2 frequency (p=0.0139 for 1-3 vs 0 events; p=0.0172 for ≥4 vs 0) were predictors of attaining dTIR ≥70% (Table).

HbA1c, insulin dose, and hypoglycemia frequency at BL were predictors of achieving target dTIR ≥70% in people with T2D advancing therapy with iGlarLixi.

Disclosure

I.Hramiak: Research Support; Eli Lilly and Company, Novo Nordisk, Sanofi, Speaker's Bureau; Canadian Medical & Surgical Knowledge Translation Research Group (CMS), Insulet Corporation, Medtronic, Merck & Co., Inc., Bayer Inc. J.P.Frias: Advisory Panel; Becton, Dickinson and Company, Pfizer Inc., Sanofi, Consultant; Akero Therapeutics, Inc., 89bio, Inc., Aimmune, Boehringer Ingelheim Inc., Eli Lilly and Company, Carmot Therapeutics, Inc., Echosens, Merck & Co., Inc., Metacrine, Inc., Novo Nordisk, Pfizer Inc., Sanofi, Employee; Ionis Pharmaceuticals, Research Support; Akero Therapeutics, Inc., 89bio, Inc., Altimmune, Axcella Health Inc., Boehringer Ingelheim Inc., Eli Lilly and Company, Intercept Pharmaceuticals, Inc., Carmot Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Madrigal Pharmaceuticals, Inc., Merck & Co., Inc., Metacrine, Inc., Novo Nordisk, Oramed Pharmaceuticals, Novartis, Pfizer Inc., Sanofi, Speaker's Bureau; Eli Lilly and Company, Sanofi. H.Aydin: Advisory Panel; Sanofi, Novo Nordisk, Boehringer Ingelheim Inc., Speaker's Bureau; Novo Nordisk. F.Lauand: Employee; Sanofi. L.Melas-melt: None. E.Souhami: Employee; Sanofi, Stock/Shareholder; Sanofi. M.Haluzik: Advisory Panel; Novo Nordisk, Lilly Diabetes, Boehringer-Ingelheim, Research Support; Sanofi, Speaker's Bureau; Abbott, AstraZeneca. J.Rosenstock: Advisory Panel; Applied Therapeutics Inc., Boehringer Ingelheim Inc., Eli Lilly and Company, Novo Nordisk, Oramed Pharmaceuticals, Sanofi, Zealand Pharma A/S, Intarcia Therapeutics, Inc., Hanmi Pharm. Co., Ltd., Research Support; Applied Therapeutics Inc., Boehringer Ingelheim Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis, Novo Nordisk, Pfizer Inc., Sanofi, Intarcia Therapeutics, Inc.

Funding

Sanofi